How to Evaluate a Clinical Research Organization: Sponsor Due-Diligence Checklist
CRO selection is more than a procurement exercise. Sponsors need to test whether the provider fits the protocol, can support the required geography and functions, operates under appropriate quality and data controls, and can deliver the study through a competent team with clear governance.
Before selection
Why CRO due diligence matters
Before transferring important trial-related activities, a sponsor should assess whether the service provider is suitable for the assigned work and define how those activities will be overseen. Outsourcing does not remove the sponsor’s responsibility for appropriate oversight of sponsor trial-related activities.
01 Define the sponsor need before contacting CROs Clarify scope, outsourcing model, retained responsibilities and study risks first.
Start with a precise sponsor brief
A weak vendor selection often starts with an unclear request for proposal. Before approaching CROs, define the study, the functions to be outsourced and the responsibilities that will remain internal.
Study scope
Define phase or study stage, product type, countries, expected sites, participant population, key endpoints, timeline pressure and major operational dependencies.
Outsourcing model
Clarify whether the sponsor needs full-service delivery, FSP support, regional execution or defined specialist functions such as biometrics or pharmacovigilance.
Oversight model
Document which decisions remain with the sponsor, who approves key deliverables and how risks, changes and escalations will be governed.
02 Study, service, therapeutic and product fit Confirm that the CRO’s actual experience matches the protocol—not just its marketing category.
Test fit against the specific study
| Area | Due-diligence question | Useful evidence |
|---|---|---|
| Service scope | Which functions will the CRO perform directly, and which will be subcontracted? | Responsibility matrix, proposal assumptions, service descriptions. |
| Study design | Has the CRO supported comparable study designs, endpoints or operational complexity? | Anonymized study summaries, feasibility assumptions, project examples. |
| Therapeutic area | Does the proposed team have meaningful experience in the relevant disease area or adjacent indication? | Team profiles, recent comparable work, scientific or operational experience. |
| Product type | Has the CRO worked with the relevant drug, biologic, vaccine, device, diagnostic, digital product or advanced therapy? | Product-specific study experience, regulatory and operational examples. |
| Patient population | Does the CRO understand recruitment constraints, eligibility criteria, site burden and visit complexity? | Feasibility rationale, recruitment assumptions, site-selection logic. |
03 Geography, sites and regulatory capability Assess operational reach, site feasibility and jurisdiction-specific regulatory support.
Geographic reach should be operational, not cosmetic
Country and site capability
Review recent country experience, local project-management or monitoring coverage, site-identification methods, investigator workload assessment and recruitment assumptions.
Regulatory and ethics support
Clarify who prepares, reviews, submits, tracks and retains each regulatory or ethics document in every target jurisdiction.
- Which target countries has the CRO recently supported for comparable work?
- How are sites identified, qualified and activated?
- What process is used to validate recruitment feasibility assumptions?
- How are translations, local documents and country-specific timelines managed?
- Which party owns each regulatory or ethics activity?
- How are delays, authority questions and document changes escalated?
04 Quality, data, technology and safety Review quality maturity, electronic systems, cybersecurity, data governance and PV responsibilities.
Assess controls, not just capabilities
Quality systems
| Quality area | What to review |
|---|---|
| QMS and SOP governance | Quality policy, QMS overview, SOP governance, document control and change management. |
| Training and competency | Role-specific training, GCP training process, project training and competency oversight. |
| Deviations and CAPA | Issue classification, investigation, root cause, corrective action and effectiveness follow-up. |
| Audit and inspection readiness | Record retrieval, audit support, significant finding escalation and inspection-support process. |
| Business continuity | Continuity plans for key staff, systems, sites, data and critical third parties. |
Data and electronic systems
System governance
Review validation or qualification approach, access controls, audit trails, change control and vendor oversight.
Cybersecurity & privacy
Review security safeguards, incident escalation, third-party controls, backup and recovery for sensitive trial and participant information.
Data lifecycle
Clarify data capture, review, reconciliation, export, retention, archive, transfer and permitted use.
Safety and pharmacovigilance
Where safety activities fall within scope, confirm responsibilities for adverse-event intake, serious adverse-event processing, medical review, reporting support, reconciliation, safety systems and aggregate or post-marketing activities as applicable.
05 Proposed team, subcontractors and governance Evaluate the people assigned to the study and the third parties behind the delivery model.
Evaluate the team you are buying—not only the CRO brand
| Area | Questions to ask | Evidence |
|---|---|---|
| Project leadership | Who will lead the study, and what comparable experience do they have? | Proposed project-lead profile, availability and study experience. |
| Clinical operations | Who will manage startup, monitoring and site performance? | CTM/CRA experience, country coverage and monitoring model. |
| Regulatory / data / safety | Who owns the specialist functions required by this protocol? | Functional-team profiles and responsibility matrix. |
| Continuity | How are turnover, absence and role substitutions managed? | Backup plan, succession approach and substitution process. |
Subcontractors and critical vendors
- Which functions are subcontracted?
- Which subcontractors are critical to study delivery?
- Who qualifies and oversees them?
- How are data and responsibilities transferred between parties?
- How are vendor failures, incidents and replacements handled?
- Does further subcontracting require sponsor notification or approval where agreed?
Governance and escalation
Define meeting cadence, decision rights, escalation thresholds, risk-log ownership, change control, quality review, performance metrics and sponsor approval points before the study begins.
06 Budget, contract, data access and transition Test proposal realism, change-order exposure, record access and exit arrangements.
Look beyond the headline price
| Commercial area | What to check |
|---|---|
| Assumptions | Sites, countries, participants, screen failure, recruitment rate, monitoring frequency, data volume and project duration. |
| Pass-through costs | Regulatory fees, site payments, travel, translations, labs, technology, logistics and other third-party costs. |
| Change orders | Triggers, unit rates, approval workflow, timing impact and documentation requirements. |
| Payment milestones | Whether payments align with measurable deliverables and progress. |
| Termination and transition | Closeout, data transfer, document handover, system access, outstanding vendors and transition assistance. |
Data, records and access rights
Contracts and associated agreements should clearly define ownership, custodianship, access, retention, transfer and permitted use of relevant trial data, records and deliverables, consistent with applicable law, GCP and the responsibilities of the sponsor, investigator/institution and service providers.
- Which records are sponsor records and which remain with the investigator/institution?
- Who controls vendor-hosted systems and exports?
- What sponsor access is available during the study?
- What happens after database lock or study closeout?
- How are records transferred if the CRO is replaced?
- What happens after merger, acquisition, restructuring or platform change?
07 Mandatory gates, red flags and shortlist scoring Do not let a high average score hide a critical deficiency.
Use a two-stage selection model
Stage 1 — Mandatory gates
Before weighted scoring, define study-specific conditions that a CRO must satisfy to remain in the shortlist.
Stage 2 — Weighted comparison
Only CROs that pass the mandatory gates should proceed to comparative scoring. The example below is illustrative and is not the CareerAidHub CRO Ranking Methodology.
| Criterion | Illustrative weight | Rating | Weighted points | Evidence / rationale |
|---|---|---|---|---|
| Study and service fit | 15% | 1–5 | Weight × (rating ÷ 5) | Document key evidence. |
| Therapeutic / product fit | 12% | 1–5 | Weight × (rating ÷ 5) | Document relevant experience. |
| Geography / sites | 13% | 1–5 | Weight × (rating ÷ 5) | Document country and site evidence. |
| Regulatory capability | 10% | 1–5 | Weight × (rating ÷ 5) | Document assigned scope. |
| Quality systems | 15% | 1–5 | Weight × (rating ÷ 5) | Document QMS and risk controls. |
| Data / technology | 12% | 1–5 | Weight × (rating ÷ 5) | Document system and data controls. |
| Proposed team | 10% | 1–5 | Weight × (rating ÷ 5) | Document named-team fit. |
| Governance / communication | 8% | 1–5 | Weight × (rating ÷ 5) | Document escalation model. |
| Commercial clarity | 5% | 1–5 | Weight × (rating ÷ 5) | Document assumptions and change risk. |
1 — Major gaps
Poor fit or significant unresolved deficiencies.
3 — Acceptable
Adequately supported and broadly fit for purpose.
5 — Exceptional fit
Very strong study-specific fit with convincing supporting evidence.
Interpret red flags by severity
Clarification issue
Missing or ambiguous information that can reasonably be resolved.
Material concern
A weakness that could affect suitability and requires mitigation.
Critical issue
A potentially disqualifying risk unless satisfactorily resolved.
08 RFI/RFP questions and practical evidence requests Ask comparable questions and request only information the CRO is permitted to share.
Make CRO responses easier to compare
| Question | Useful evidence |
|---|---|
| Describe recent comparable study experience, including role, geography and study complexity. | Anonymized study summaries or structured experience table. |
| Which services will you perform directly and which will be subcontracted? | Responsibility matrix and critical-vendor map. |
| How is quality governed for this service scope? | QMS overview, relevant SOP index and quality-governance summary. |
| Who will perform the work? | Proposed team profiles, allocation and backup model. |
| How are electronic systems and data governed? | System-governance, access-control, security and data-lifecycle summary. |
| How are risks and issues escalated? | Governance structure, escalation pathway and sample risk framework. |
| What assumptions drive the proposal? | Assumption sheet, unit rates and change-order triggers. |
| How will study records and data be transitioned at closeout or termination? | Transition, closeout and data-transfer process summary. |
09 FAQs, references and final decision checklist Concise answers plus a final sponsor review before selection.
Frequently asked questions
Concise answers to common sponsor questions before CRO selection.
What is CRO due diligence?
CRO due diligence is a structured sponsor review of study fit, relevant experience, quality systems, data controls, team capability, subcontractors, governance, commercial assumptions and transition risk before engagement.
Is CRO due diligence the same as a quality audit?
No. Due diligence may review quality evidence, but a formal quality audit is a separate structured quality-assurance activity. Neither is the same as a regulatory inspection.
What evidence should sponsors request?
Useful evidence can include service descriptions, proposed-team profiles, anonymized comparable-study summaries, QMS information, subcontractor oversight processes, data/system governance summaries, commercial assumptions and transition plans.
Should the lowest-cost CRO be selected?
Not automatically. Compare the realism of assumptions, total cost drivers, change-order exposure, team capability and study-specific risk—not only the headline proposal value.
Can a regional or specialist CRO be the best fit?
Yes. A smaller, regional or specialist CRO may be preferable when its documented experience, local knowledge, proposed team and operating model better match the study.
Final sponsor decision checklist
- Mandatory gate criteria passed.
- Study and service scope understood.
- Proposed team reviewed.
- Subcontractors and critical vendors understood.
- Quality and data controls acceptable.
- Regulatory and country responsibilities documented.
- Commercial assumptions and change triggers understood.
- Data access, retention and transition terms reviewed.
- Selection rationale documented with evidence.
- Appropriate quality, legal, privacy and regulatory review completed as required.
